RayPilot HypoCath_ Next Generation real-time tumor tracking for radiotherapy against prostate cancer
|Coordinator||MICROPOS MEDICAL AB (PUBL) - Micropos Medical AB|
|Funding from Vinnova||SEK 500 000|
|Project duration||December 2018 - May 2019|
Purpose and goal
The overall goal of this project is to develop an enhanced (non-invasive) version of our RayPilot solution and realise its international commercialisation. The work plan split into 2 Phases: Phase 1 (for this application), where we will dedicate 4 months to complete the technical, commercial, and financial feasibility analysis of RayPilot® HypoCath Phase 2 (later funding application), with 18 months to conduct the technical developments and prepare the international commercialisation of the upgraded product at EU level, our focus during the initial years.
Expected results and effects
The commercialisation of HypoCath will represent significant growth to Micropos, generating new IP, additional €6.63 million revenues by 2024, and at least 15 new direct jobs.
Planned approach and implementation
Phase 1, where we will dedicate 4 months to complete the technical, commercial, and financial feasibility analysis of RayPilot® HypoCath. See further on Page 5 in attached PDF-file with objectives in Table 2 and activities detailed in Section 3, Work Plan.